Alentis
Basel, CH · Founded 2019 · 70 employees on LinkedIn · 12 known investors
Find your way into Alentis
184 people in our graph share verified history with the Alentis team — schools, employers, funds. One of them is your warm intro.
Rushika Fernandopulleunlockedknows Thomas Baumert · together at Harvard Medical School (overlapped)
×9knows the team · via Heidelberg University
knows the team · via Université de Strasbourg
knows the team · via The University of Freiburg
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease. It operates as a clinical-stage biopharmaceutical company advancing small molecules, antibodies, and related drug programs in oncology and fibrotic diseases.
Founders & leadership
Alentis was founded in 2019 by Thomas Baumert.
TB
Thomas BaumertinFounderThomas Baumert holds an MD from the University of Heidelberg and completed training in internal medicine and gastroenterology at Ludwig Maximilians University Munich and the University Hospital Freiburg. He served as a fellow at Harvard Medical School and the NIH Liver Diseases Branch, became an associate professor in Freiburg, and is currently a professor of medicine at the University of Strasbourg and director of the Inserm Institute for Translational Medicine, with research focused on fibrosis and cancer therapies; he founded Alentis Therapeutics.
MP
Mark PruzanskiinChief Executive Officer
LM
Luigi ManentiinChief Medical Officer
JF
Jon FreveinChief Financial Officer
BY
Bryan YooninGeneral Counsel and Chief Administrative OfficerExecutive Officer at Terns Pharmaceuticals
AV
Aditya VenugopalinChief Business Officer
AT
Alberto TosoinChief Scientific Officer
RM
Roberta MarchioneinChief Technology Officer
Investors · 12
Avego BioScience Capital✓ verifiedAlpharetta
BioMedPartners✓ verifiedBasel · $648K – $6.5M
Frazier Life Sciences✓ verifiedPalo Alto
Jeito Capital✓ verifiedParis
Longitude Capital✓ verifiedMenlo Park · $10M – $30M
Novo Holdings✓ verifiedCopenhagen · $1.1M – $54M
OrbiMed✓ verifiedNew York · $1M – $75M
RA Capital✓ verifiedBoston
Bpifrance✓ verifiedParis, Ile-De-France · $270K
Catalio Capital Management✓ verifiedNew York
Catalio Capital Management, LPNew York
Pureos BioventuresPfäffikon
In the news
Frequently asked questions
- What does Alentis do?
- Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease. It operates as a clinical-stage biopharmaceutical company advancing small molecules, antibodies, and related drug programs in oncology and fibrotic diseases.
- Who founded Alentis?
- Alentis was founded by Thomas Baumert in 2019.
- Who are Alentis's investors?
- Alentis's investors include Avego BioScience Capital, BioMedPartners, Frazier Life Sciences, Jeito Capital, Longitude Capital, Novo Holdings, OrbiMed, RA Capital and 4 more.
- Where is Alentis headquartered?
- Alentis is headquartered in Basel, CH.